Sudeep Pharma Posts 49% Revenue Jump on Acquisition, Lists Successfully

CHEMICALS
Whalesbook Logo
AuthorRiya Kapoor|Published at:
Sudeep Pharma Posts 49% Revenue Jump on Acquisition, Lists Successfully
Overview

Sudeep Pharma Limited reported robust Q3 FY26 results, with consolidated revenue soaring 49.15% year-on-year to ₹17,233.56 Lakhs, boosted by the acquisition of Nutrition Supplies & Services (Ireland) Limited. Consolidated Profit After Tax (PAT) surged 66.13% to ₹4,769.91 Lakhs, and diluted EPS rose to ₹4.29. Standalone PAT also grew 30.21% YoY. The company successfully completed its IPO in November 2025, listing on NSE and BSE, with ₹7,581.40 Lakhs of net proceeds remaining unutilized.

📉 The Financial Deep Dive

Sudeep Pharma Limited has unveiled strong financial results for the third quarter and nine months ended December 31, 2025, underscoring significant growth, particularly on a consolidated basis, following strategic acquisitions and its recent public listing.

The Numbers:

  • Standalone Performance (Q3 FY26 vs. Q3 FY25):
    • Revenue from operations grew 8.14% YoY to ₹9,028.25 Lakhs.
    • Profit After Tax (PAT) witnessed a substantial rise of 30.21% YoY to ₹2,686.88 Lakhs.
    • Earnings Per Share (EPS) increased to ₹2.42 from ₹1.90 in the prior year period.
  • Standalone Performance (9M FY26 vs. 9M FY25):
    • Revenue from operations rose 2.56% YoY to ₹25,833.83 Lakhs.
    • PAT increased by 30.67% YoY to ₹8,181.51 Lakhs.
  • Consolidated Performance (Q3 FY26 vs. Q3 FY25):
    • Revenue from operations surged 49.15% YoY to ₹17,233.56 Lakhs.
    • Consolidated PAT jumped 66.13% YoY to ₹4,769.91 Lakhs.
    • Diluted EPS rose to ₹4.29 from ₹2.65 YoY.
  • Consolidated Performance (9M FY26 vs. 9M FY25):
    • Revenue increased 33.52% YoY to ₹45,991.93 Lakhs.
    • Consolidated PAT grew 33.00% YoY to ₹12,574.65 Lakhs.

The Quality & Drivers:

The primary growth driver for the consolidated figures is the acquisition of Nutrition Supplies & Services (Ireland) Limited (NSS), which became a step-down subsidiary effective May 22, 2025. This strategic move, involving an 85% equity stake for ₹12,857.63 Lakhs and a provisional goodwill recognition of ₹6,094.94 Lakhs, has significantly bolstered Sudeep Pharma's top and bottom lines. The 'Other income' also saw a notable year-on-year increase in both standalone periods, contributing to PAT growth.

The company operates across two key segments: 'Pharmaceutical, food and nutrition' and 'Speciality ingredients'.

Financial Snapshot & Corporate Actions:

Sudeep Pharma successfully completed its Initial Public Offering (IPO) on November 28, 2025, with its shares listing on both the NSE and BSE. As of December 31, 2025, a substantial ₹7,581.40 Lakhs of the net IPO proceeds remain unutilized and are held as term deposits. This liquidity provides strategic flexibility for future growth initiatives or debt reduction. The Board also approved the appointment of M/s Sharp & Tannan Associate as the Internal Auditor for FY 2026-27.

🚩 Risks & Outlook

While the growth is commendable, key considerations for investors include the successful integration of the NSS acquisition and its continued contribution to earnings. The substantial unutilized IPO proceeds present an opportunity, but their deployment strategy will be crucial. The company operates in dynamic segments with evolving regulatory landscapes and competitive pressures. Investors should monitor the performance of both the pharmaceutical and specialty ingredients segments, as well as any strategic announcements regarding the utilization of IPO funds or further acquisitions.

Disclaimer:This content is for educational and informational purposes only and does not constitute investment, financial, or trading advice, nor a recommendation to buy or sell any securities. Readers should consult a SEBI-registered advisor before making investment decisions, as markets involve risk and past performance does not guarantee future results. The publisher and authors accept no liability for any losses. Some content may be AI-generated and may contain errors; accuracy and completeness are not guaranteed. Views expressed do not reflect the publication’s editorial stance.